Cargando…
The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update
The international, phase III, multi-centre AZA-001 trial demonstrated azacitidine (AZA) is the first treatment to significantly extend overall survival (OS) in higher risk myelodysplastic syndromes (MDS) patients (Fenaux (2007) Blood 110 817). The current treatment paradigm, which is based on a rela...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cancer Intelligence
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234059/ https://www.ncbi.nlm.nih.gov/pubmed/22275990 http://dx.doi.org/10.3332/ecancer.2008.118 |
_version_ | 1782218464518209536 |
---|---|
author | Silverman, LR Fenaux, P Mufti, GJ Santini, V Hellström-Lindberg, E Gattermann, N Sanz, G List, AF Gore, SD Seymour, JF Backstrom, J McKenzie, D Beach, CL |
author_facet | Silverman, LR Fenaux, P Mufti, GJ Santini, V Hellström-Lindberg, E Gattermann, N Sanz, G List, AF Gore, SD Seymour, JF Backstrom, J McKenzie, D Beach, CL |
author_sort | Silverman, LR |
collection | PubMed |
description | The international, phase III, multi-centre AZA-001 trial demonstrated azacitidine (AZA) is the first treatment to significantly extend overall survival (OS) in higher risk myelodysplastic syndromes (MDS) patients (Fenaux (2007) Blood 110 817). The current treatment paradigm, which is based on a relationship between complete remission (CR) and survival, is increasingly being questioned (Cheson (2006) Blood 108 419). Results of AZA-001 show CR is sufficient but not necessary to prolong OS (List (2008) Clin Oncol 26 7006). Indeed, the AZA CR rate in AZA-001 was modest (17%), while partial remission (PR, 12%) and haematological improvement (HI, 49%) were also predictive of prolonged survival. This analysis was conducted to assess the median number of AZA treatment cycles associated with achievement of first response, as measured by IWG 2000-defined CR, PR or HI (major + minor). The number of treatment cycles from first response to best response was also measured. |
format | Online Article Text |
id | pubmed-3234059 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | Cancer Intelligence |
record_format | MEDLINE/PubMed |
spelling | pubmed-32340592012-01-24 The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update Silverman, LR Fenaux, P Mufti, GJ Santini, V Hellström-Lindberg, E Gattermann, N Sanz, G List, AF Gore, SD Seymour, JF Backstrom, J McKenzie, D Beach, CL Ecancermedicalscience Short Communications The international, phase III, multi-centre AZA-001 trial demonstrated azacitidine (AZA) is the first treatment to significantly extend overall survival (OS) in higher risk myelodysplastic syndromes (MDS) patients (Fenaux (2007) Blood 110 817). The current treatment paradigm, which is based on a relationship between complete remission (CR) and survival, is increasingly being questioned (Cheson (2006) Blood 108 419). Results of AZA-001 show CR is sufficient but not necessary to prolong OS (List (2008) Clin Oncol 26 7006). Indeed, the AZA CR rate in AZA-001 was modest (17%), while partial remission (PR, 12%) and haematological improvement (HI, 49%) were also predictive of prolonged survival. This analysis was conducted to assess the median number of AZA treatment cycles associated with achievement of first response, as measured by IWG 2000-defined CR, PR or HI (major + minor). The number of treatment cycles from first response to best response was also measured. Cancer Intelligence 2008-12-08 /pmc/articles/PMC3234059/ /pubmed/22275990 http://dx.doi.org/10.3332/ecancer.2008.118 Text en Copyright: © the authors; licensee ecancermedicalscience. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Short Communications Silverman, LR Fenaux, P Mufti, GJ Santini, V Hellström-Lindberg, E Gattermann, N Sanz, G List, AF Gore, SD Seymour, JF Backstrom, J McKenzie, D Beach, CL The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update |
title | The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update |
title_full | The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update |
title_fullStr | The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update |
title_full_unstemmed | The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update |
title_short | The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update |
title_sort | effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update |
topic | Short Communications |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234059/ https://www.ncbi.nlm.nih.gov/pubmed/22275990 http://dx.doi.org/10.3332/ecancer.2008.118 |
work_keys_str_mv | AT silvermanlr theeffectsofcontinuedazacitidinetreatmentcyclesonresponseinhigherriskpatientswithmyelodysplasticsyndromesanupdate AT fenauxp theeffectsofcontinuedazacitidinetreatmentcyclesonresponseinhigherriskpatientswithmyelodysplasticsyndromesanupdate AT muftigj theeffectsofcontinuedazacitidinetreatmentcyclesonresponseinhigherriskpatientswithmyelodysplasticsyndromesanupdate AT santiniv theeffectsofcontinuedazacitidinetreatmentcyclesonresponseinhigherriskpatientswithmyelodysplasticsyndromesanupdate AT hellstromlindberge theeffectsofcontinuedazacitidinetreatmentcyclesonresponseinhigherriskpatientswithmyelodysplasticsyndromesanupdate AT gattermannn theeffectsofcontinuedazacitidinetreatmentcyclesonresponseinhigherriskpatientswithmyelodysplasticsyndromesanupdate AT sanzg theeffectsofcontinuedazacitidinetreatmentcyclesonresponseinhigherriskpatientswithmyelodysplasticsyndromesanupdate AT listaf theeffectsofcontinuedazacitidinetreatmentcyclesonresponseinhigherriskpatientswithmyelodysplasticsyndromesanupdate AT goresd theeffectsofcontinuedazacitidinetreatmentcyclesonresponseinhigherriskpatientswithmyelodysplasticsyndromesanupdate AT seymourjf theeffectsofcontinuedazacitidinetreatmentcyclesonresponseinhigherriskpatientswithmyelodysplasticsyndromesanupdate AT backstromj theeffectsofcontinuedazacitidinetreatmentcyclesonresponseinhigherriskpatientswithmyelodysplasticsyndromesanupdate AT mckenzied theeffectsofcontinuedazacitidinetreatmentcyclesonresponseinhigherriskpatientswithmyelodysplasticsyndromesanupdate AT beachcl theeffectsofcontinuedazacitidinetreatmentcyclesonresponseinhigherriskpatientswithmyelodysplasticsyndromesanupdate AT silvermanlr effectsofcontinuedazacitidinetreatmentcyclesonresponseinhigherriskpatientswithmyelodysplasticsyndromesanupdate AT fenauxp effectsofcontinuedazacitidinetreatmentcyclesonresponseinhigherriskpatientswithmyelodysplasticsyndromesanupdate AT muftigj effectsofcontinuedazacitidinetreatmentcyclesonresponseinhigherriskpatientswithmyelodysplasticsyndromesanupdate AT santiniv effectsofcontinuedazacitidinetreatmentcyclesonresponseinhigherriskpatientswithmyelodysplasticsyndromesanupdate AT hellstromlindberge effectsofcontinuedazacitidinetreatmentcyclesonresponseinhigherriskpatientswithmyelodysplasticsyndromesanupdate AT gattermannn effectsofcontinuedazacitidinetreatmentcyclesonresponseinhigherriskpatientswithmyelodysplasticsyndromesanupdate AT sanzg effectsofcontinuedazacitidinetreatmentcyclesonresponseinhigherriskpatientswithmyelodysplasticsyndromesanupdate AT listaf effectsofcontinuedazacitidinetreatmentcyclesonresponseinhigherriskpatientswithmyelodysplasticsyndromesanupdate AT goresd effectsofcontinuedazacitidinetreatmentcyclesonresponseinhigherriskpatientswithmyelodysplasticsyndromesanupdate AT seymourjf effectsofcontinuedazacitidinetreatmentcyclesonresponseinhigherriskpatientswithmyelodysplasticsyndromesanupdate AT backstromj effectsofcontinuedazacitidinetreatmentcyclesonresponseinhigherriskpatientswithmyelodysplasticsyndromesanupdate AT mckenzied effectsofcontinuedazacitidinetreatmentcyclesonresponseinhigherriskpatientswithmyelodysplasticsyndromesanupdate AT beachcl effectsofcontinuedazacitidinetreatmentcyclesonresponseinhigherriskpatientswithmyelodysplasticsyndromesanupdate |